CA3236111A1 - Procedes pour traiter un lymphome folliculaire en rechute / refractaire avec mosunetuzumab et lenalidomide - Google Patents

Procedes pour traiter un lymphome folliculaire en rechute / refractaire avec mosunetuzumab et lenalidomide Download PDF

Info

Publication number
CA3236111A1
CA3236111A1 CA3236111A CA3236111A CA3236111A1 CA 3236111 A1 CA3236111 A1 CA 3236111A1 CA 3236111 A CA3236111 A CA 3236111A CA 3236111 A CA3236111 A CA 3236111A CA 3236111 A1 CA3236111 A1 CA 3236111A1
Authority
CA
Canada
Prior art keywords
mosunetuzumab
lenalidomide
dosing
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236111A
Other languages
English (en)
Inventor
Catherine GRANIER
Andrea KNAPP
Chi-Chung Li
Carol Elaine O'hear
Enkhtsetseg PUREV
Michael C. Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CA3236111A1 publication Critical patent/CA3236111A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

La présente invention concerne le traitement de sujets soufrant d'un lymphome folliculaire (FL) en rechute et/ou réfractaire (R/R). Plus spécifiquement, l'invention concerne le traitement de sujets soufrant d'un FL R/R par l'administration d'une combinaison de mosunetuzumab et de lénalidomide.
CA3236111A 2021-10-29 2021-10-29 Procedes pour traiter un lymphome folliculaire en rechute / refractaire avec mosunetuzumab et lenalidomide Pending CA3236111A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (fr) 2021-10-29 2021-10-29 Procédés pour traiter un lymphome folliculaire en rechute / réfractaire avec mosunetuzumab et lénalidomide

Publications (1)

Publication Number Publication Date
CA3236111A1 true CA3236111A1 (fr) 2023-05-04

Family

ID=86158448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236111A Pending CA3236111A1 (fr) 2021-10-29 2021-10-29 Procedes pour traiter un lymphome folliculaire en rechute / refractaire avec mosunetuzumab et lenalidomide

Country Status (2)

Country Link
CA (1) CA3236111A1 (fr)
WO (1) WO2023075798A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138045C (fr) * 2019-05-14 2024-02-20 Genentech, Inc. Procedes d'utilisation d'immunoconjugues anti-cd79b pour traiter un lymphome folliculaire

Also Published As

Publication number Publication date
WO2023075798A9 (fr) 2023-06-29
WO2023075798A1 (fr) 2023-05-04

Similar Documents

Publication Publication Date Title
US10544223B2 (en) Combination therapy with an anti-axl antibody-drug conjugate
US11583577B2 (en) Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
CN110636861B (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
US20200216542A1 (en) Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
KR20220020331A (ko) 항-cd25 항체 약물 접합체 및 추가 제제를 포함하는 조합 요법
US20220305132A1 (en) Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
US20230190932A1 (en) Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide
CA3236111A1 (fr) Procedes pour traiter un lymphome folliculaire en rechute / refractaire avec mosunetuzumab et lenalidomide
CA3196191A1 (fr) Dosage pour le traitement avec des anticorps bispecifiques anti-cd20/anti-cd3 et des conjugues anticorps anti-cd79b-medicament
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法
US20240043553A1 (en) Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide
US20220411528A1 (en) Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US20220380466A1 (en) Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies
US20230416391A1 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patients
TW202409075A (zh) 用莫蘇妥珠單抗及來那度胺治療先前未經治療的濾泡性淋巴瘤之方法
CA3223534A1 (fr) Methodes et compositions pour le traitement du cancer
WO2022074033A1 (fr) Polythérapie